Cytori Appoints a New Vice President of Finance and Chief Financial
Officer

August 18, 2014 01:30 PM Eastern Daylight Time

SAN DIEGO--(BUSINESS WIRE)--Cytori
Therapeutics (NASDAQ: CYTX) today announced that Mr. Tiago Girão has
been appointed Vice President of Finance and Chief Financial Officer
(CFO), with an effective start date of September 2, 2014.

“Mr. Girão is an ideal candidate to take over the role of Vice President
of Finance and Chief Financial Officer at this time in our corporate
development,” said Dr. Hedrick. “He has a particularly strong background
in public company finance and accounting practices as well as
international operations, all important issues for us today. The added
benefit to Cytori is that he has an in-depth, long standing knowledge of
Cytori’s technology and history from his previous tenure at KPMG in
which he functioned as the senior account manager for Cytori. This will
enable him to get up to speed quickly and we are extremely excited to
have him on our team.”

“I have been following Cytori and their groundbreaking technology for
more than eight years and am very excited by the technology’s potential
to transform patients’ lives,” said Mr. Girão. “I am 100% dedicated to
strengthening Cytori’s global financial operations and to strengthening
the balance sheet, thereby growing shareholder value.”

Mr. Girão joins Cytori Therapeutics as Vice President of Finance and CFO
from NuVasive,
Inc. where he recently served as International Controller. As part
of his role, Mr. Girão was responsible for leading a 20 person finance
team, and for overseeing all aspects of international finance and
accounting operations. He was also involved in all major business and
asset acquisitions and was the lead corporate financial and accounting
executive for NuVasive’s foreign units, including those in Japan, Latin
America, Europe and Australia. Prior to his International Controller
role, he served as Director, Financial Reporting, where he managed a
team responsible for all corporate technical accounting and SEC related
matters.

Prior to joining NuVasive, Mr. Girão served as Senior Manager, Assurance
at KPMG, Cytori’s independent audit firm and was responsible for
Cytori’s account for six years. Prior to joining KPMG, Mr. Girão was a
senior accountant for Ernst & Young in Brazil. Mr. Girão is a certified
public accountant with 14 years experience in the accounting, finance
and reporting for U.S. public companies and substantial experience in
global finance and operations. Mr. Girão is originally from Brazil,
speaks fluent Portuguese and holds a B.A. in Accounting from the
University of Fortaleza.

Cytori announced on August 11, 2014 that former CFO Mark Saad had
accepted another opportunity and would be leaving the Company, effective
August 11. Mr. Saad will remain as a consultant to Cytori for a period
of time and will continue to support the new VP Finance and CFO as well
as the management team during the transition period.

About Cytori Therapeutics

Cytori Therapeutics is developing cell therapies based on autologous
adipose-derived regenerative cells (ADRCs) to treat cardiovascular
disease and other medical conditions. Our scientific data suggest ADRCs
improve blood flow, moderate the inflammatory response and keep tissue
at risk of dying alive. As a result, we believe these cells can be
applied across multiple “ischemic” conditions. These therapies are made
available to the physician and patient at the point-of-care by Cytori’s
proprietary technologies and products, including the Celution® System
product family. www.cytori.com